Avivit Peer speaks with Elizabeth Plimack about the KEYMAKER-U04 substudy 04B, a phase 1/2 randomized trial in first-line metastatic urothelial carcinoma testing whether adding favezelimab or ...
Lee et al, 1 comprising authors from a number of institutions, published a retrospective observational study conducted on 147 consecutive patients who underwent endoscopic enucleation of the prostate ...
Neurogenic bladder is a condition with risk of renal damage. Its diagnosis and timely management improve the renal prognosis of pediatric patients. As an initiative of the Colombian Association of ...
The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without question, there ...
Sophia Coraci discusses an analysis of 104 treatment-naive prostate cancer patients correlating PSMA PET SUVmax with Decipher genomic classifier scores. PSMA PET imaging occurred within 35 days of ...
Treatment of idiopathic male infertility has traditionally relied on the empirical use of oral agents such as clomiphene citrate and aromatase inhibitors, often prescribed without rigorous endocrine ...
Patrick Hensley discusses research led by Kim Toumazos and Spencer Bell analyzing patient-reported outcome incorporation in non-muscle-invasive bladder cancer trials. The ClinicalTrials.gov database ...
Radiotherapy of the pelvis and abdomen can have significant negative long-term effects on the bladder and urethra. Applying the PICO criteria, we reviewed the MEDLINE/PUBMED databases over a 10-year ...
Thomas Powles presents IZABRIGHT, a global randomized Phase III trial testing izalontamab brengitecan, a dual HER1/HER3 antibody-drug conjugate with topoisomerase payload, versus platinum-based ...
Perioperative immune checkpoint inhibitors (ICIs) combined with radical cystectomy (RC) represent an emerging paradigm for optimizing outcomes in muscle-invasive bladder cancer (MIBC). Our aim was to ...
Reno, Nevada (UroToday.com) -- Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results